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Clinical and translational informaticsWe live in the genomic era of medicine, where a patient's genomic/molecular data is becoming increasingly
important for disease diagnosis, identiﬁcation of targeted therapy, and risk assessment for adverse reactions.
However, decoding the genomic test results and integrating it with clinical data for retrospective studies and co-
hort identiﬁcation for prospective clinical trials is still a challenging task. In order to overcome these barriers, we
developed an overarching enterprise informatics framework for translational research and personalized medi-
cine called Synergistic Patient and Research Knowledge Systems (SPARKS) and a suite of tools called Oncology
Data Retrieval Systems (OncDRS). OncDRS enables seamless data integration, secure and self-navigated query
and extraction of clinical and genomic data from heterogeneous sources. Within a year of release, the system
has facilitated more than 1500 research queries and has delivered data for more than 50 research studies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In the past two decades, release of the human genome sequence
(Venter, et al. 2001) and development of cost effective genomic se-
quencing technologies (Wheeler et al. 2008; Bonetta 2010) have revo-
lutionized our ability to understand genomic underpinning of diseases
and tailor treatment strategies to target genomic alterations. The cur-
rent trend is to move away from single-gene based tests. Instead, next
generation sequencing (NGS) based genomic proﬁling is performed to
detectmultiple genetic alterations simultaneously, including, both com-
mon and rare sequence variants (MacConaill et al. 2009; Frampton et al.
2013; Dias-Santagata et al. 2010). Genomic proﬁling is transitioning
from research-based tests to mainstream medical care where an
individual patient's genetic proﬁle is used to guide patient care/
management (Yap and Popat 2014; Olsen and Jorgensen 2014; Larson
andWilke 2015). Detection of targetable alterations enables clinical re-
searchers to designmore efﬁcient clinical trials where tailored therapies
can be tested on selected patient cohorts that have speciﬁc clinical and
genetic/molecular features. This will allow matching of patients withssachusetts Medical School, 55
athew).
. This is an open access article underdrugs that are better suited to their molecular proﬁle, thereby reducing
attrition rate of candidate drugs (Roper et al. 2015; Dienstmann et al.
2015). Additionally, retrospective analysis of exceptional responders
(both positive and negative) helps in understanding why a particular
treatment strategy worked, or did not work, for speciﬁc patients
(Chau and Lorch 2015; Iyer et al. 2012; Printz 2015).
Informatics challenges for next generation clinical and translational
research and precisionmedicine include ability to: a) aggregate, harmo-
nize, integrate, and analyze the clinical and genomic/molecular data on
a patient over a longitudinal continuum and b) access and visualize ac-
tionable ﬁndings in a timely manner for treatment decisions (Sulakhe
et al. 2014); (Mate et al. 2011; Schriml and Mitraka 2015; Louie et al.
2007; Mathew et al. 2007). Clinical data are heterogeneous in general
and are usually stored in multiple clinical and operational systems.
The same clinical information (e.g. diagnosis)may be captured in differ-
ent clinical, pathology, radiology and cancer registry systems. These sys-
tems may not follow the same standard terminologies or ontology,
which may make deciphering the clinical phenotype a daunting task.
For example, cancer registries normally use ICD-O codes for site, histol-
ogy, and behavior, as well as other data, to describe a cancer diagnosis.
On the other hand, the hospital-billing systems often use ICD-9 codes
to record patient's diagnostic data. The fact that patient clinical informa-
tion is captured in different systems can lead to problemswith base pa-
tient population because all patients may not be present in all systems.
The extent and granularity of information in each of the systems couldthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lead to erroneous conclusions if the data analysis does not take into ac-
count such underlying differences between the systems.
In this paper, we introduce an informatics framework and a suite of
tools that we developed at Dana-Farber Cancer Institute (DFCI) for ef-
fective integration of clinical and genomic data and providing relevant
genomic results to clinical providers.
2. Methods
In 2011, DFCI and BrighamWoman's Hospital (BWH) launched Pro-
ﬁle, one of the nation's most comprehensive personalized cancer initia-
tives (http://www.precisioncancermedicine.org/research-treatment/
what-is-proﬁle/). The project expanded to Boston Children's Hospital
(BCH) in 2012. The Proﬁle initiative is expected to create one of the
world's largest databases of cancer-driven abnormalities and help ad-
vance personalized precision cancer care. In the last few years, more
than 37,000 patients have consented to have tumor tissue analyzed
for the presence of mutations and other cancer-related DNA abnormal-
ities. More than 11,000 genetic proﬁles of patients' tumors were tested
and more than 300 Proﬁle tests are expected to be performed each
month. The genetic test platforms used so far for Proﬁle include mass
spectrometric genotyping (OncoMap) (MacConaill et al. 2009) and
targeted massively parallel sequencing (OncoPanel) (Wagle et al.
2012). The OncoMap test probed 471 mutations in 41 cancer-related
genes. The OncoPanel test includes genomic data on sequence variants,
copy number alterations, and selected chromosome rearrangements of
305 genomic regions for each patient who has consented to participate
in the Proﬁle study.
To support the Proﬁle initiative, the Synergistic Patient and Research
Knowledge System (SPARKS)was established as an institution-wide in-
formatics framework, to accelerate scientiﬁc discoveries and their trans-
lation into personalized medicine and clinical practice. Three major
systems were developed under the SPARKS framework:
1. OncoTracker: enables tracking of high-level status of Proﬁle testing
related processes including requisition, consent, specimen request,
DNA extraction, and completion of genomic proﬁling and bioinfor-
matics pipeline. OncoTracker allows providers and research teams
to check on the status of proﬁle test for their patients.
2. Proﬁle Results Viewer: enables easy visualization of relevant genetic
results by care providers based on informed consent status. Results
are provided as a pathology report in ‘PDF’ format. The report high-
lights the clinical relevance of the variants detected in the patient's
biospecimen, and may include recommendations for treatment and
clinical trials when available and appropriate.
3. The Oncology Data Retrial System (OncDRS): implements policies,
standards, systems, and tools, that addressed the challenges in inte-
gration of clinical and genomic data, and data governance, across dis-
ease areas. OncDRS, which is the focus of this paper, is a self-service
application for investigators, and one-stop shop for data query, data
request, data access approval, and data extraction.
2.1. Data governance and related policies
Development of OncDRSwas guided by a set of processes and gover-
nance practices that are outlined in detail elsewhere and mentioned
only brieﬂy in here.
2.1.1. Logical separation of routine clinical data and consented research
data collection& IRB approvedmaster protocols governing data repositories
and data access
The IRB policy stipulates that identiﬁed data, obtained during rou-
tine care of a patient, can be used for research if a waiver of consent
and authorization is obtained from the IRB. Explicit patient consent is
not required for research use of data obtained during routine patientcare. However, research use of biospecimens and specimen-derived
data and linkage to clinical data requires explicit consent from patients.
In order to facilitate diversiﬁed use of both types of data, two separate
repositories: Clinical Operational and Research Information System
(CORIS) and Consented Research Data Repository (CRDR) were de-
signed for warehousing clinical and biospecimen derived research
data respectively. Two separate protocols were written to govern the
collection, archival, and access of 1) clinical data in CORIS and2) banking
of biospecimens, storing specimen derived research data in CRDR and
linkage to clinical data (Rollins and Kantoff, 2011, personal communica-
tion). The uniﬁed biospecimen and specimenderived data protocol sim-
pliﬁed consenting and linking of genomic data to clinical data.
At the time of writing this manuscript, CORIS included clinical data
captured in six different clinical and operational systems (Fig. 1).
Clinical data including scheduling, registration, and billing information,
are fetched from the clinical system (currently, GE-IDX). Laboratory test
results were obtained from Sunquest Lab System. Medications dis-
pensed in infusion clinics are sourced from Outpatient Pharmacy
System. Cancer diagnosis information on all patients initially diagnosed
or treated for cancer at the institute is recorded in the Cancer Registry
System (Metriq). Details of chemotherapy drugs, and non-chemo
drugs for patients seen at DFCI are obtained from DFCI Chemotherapy
Order Entry System. Additionally, patient entered data frompatient sur-
veys and clinical data abstracted from medical charts by disease pro-
grams through the Clinical Research Information Systems (CRIS) is
also stored in this repository. Patient enrollment on therapeutic, and an-
cillary therapeutic cancer-related clinical trials, for patients across the
DF/HCC, are received from the DF/HCC Protocol Enrollment System.
Genomic data generated from Proﬁle tests are fed into the Clinical
Research Data Repository (CRDR). Genetic abnormalities detected
with OncoPanel test include Single Nucleotide Variations (SNV), small
indels, Copy Number Variations (CNV), and chromosomal transloca-
tions. Genomic coordinates from the human genome build hg19, refer-
ence allele and alternative allele of the SNVs are fed into theweb service
of OncoTator (http://www.broadinstitute.org/oncotator/) to obtain ex-
tensive annotation of the variants and transcripts. OncoMap used a
three-tier schema while the newer OncoPanel uses a ﬁve-tier schema
(MacConaill et al. 2014) to describe clinical actionability.
Table 1 presents a snapshot of all data in OncDRS based on the data
refresh on June 2015.
2.1.2. Generalized and uniform informed consent
Proﬁle was designed as a research test that necessitates patient's
written consent for conducting the test and release of the data. A gener-
alized and uniform consent across all cancer typeswas designed and ap-
proved as part of the banking and research data protocol with three
questions for informed consent from the patient:
Q 1. Permission to analyze leftover clinically acquired specimens,
link results to medical information, bank specimens, and derivatives
for possible future research use.
Q 2. Permission to take an extra tube of blood, buccal swab and urine
for genetic analyses and storematerials for possible future research, and
share the results of the analyses after removing personal identifying
information.
Q 3. Permission to return relevant actionable results to the medical
care team and to re-contact the patient about research studies that
might be relevant for them in the future.
Currently, a proﬁle test requisition is entered for every new patient
who comes to the institute. However, sample retrieval and proﬁle test
will not start until a written consent is received from the patient. The
written consent is entered into DF/HCC Clinical Trials Management
System (CTMS) where all cancer protocol registrations are done.
Institutional policy requires that real-time checking of consentmust
be performed before a physician caring for the patient can view the Pro-
ﬁle test results and before an investigator can obtain detailed patient
level data for a research project from OncDRS (Fig. 2). The existence of
Fig. 1. OncDRS data sources and data integration pipeline. DFCI, Dana-Farber Cancer Institute; CRIS, Clinical Research Information System; CORIS, Clinical Operational and Research Infor-
mation System; CRDR, Consented Research Data Repository.
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before data release through OncDRS, not onlymaximizes patient partic-
ipation in research, but also ensures compliance with patient directives
on data use.
2.1.3. Data governance and access rules
Well-deﬁned and clearly articulated data governance and access
rules made the authentication and authorization process simple from
a system design perspective. These rules governing who can access
the system and what kind of permissions they have are outlined in
Table 2. In addition, the levels of permissions and approvals needed
from data governance groups and IRB to obtain aggregate, de-
identiﬁed, limited and identiﬁed data sets for research are shown in
Table 3.
Following these rules enables the OncDRS system to ensure that data
is only provided to users based on the “need to know” principle. The
principle of the “need to know” is enforced by two levels of review pro-
cess: disease program speciﬁc user committee review and Institutional
Review Board (IRB) review. A designated user committee is selected
by each disease program and is responsible for the scientiﬁc review ofTable 1
A snapshot of all data in OncDRS, based on the data refresh on June 2015.
Data type No. of records System type
Demographics 276,039 Clinical operations
Medical billing diagnosis 8,270,751 Clinical operations
Outpatient clinic appointments 8,442,045 Clinical operations
Cancer registry 69,297 Clinical operations
Laboratory results 64,218,515 Clinical operations
Outpatient pharmacy dispenses 6,383,140 Clinical operations
Chemotherapy order entry 4,649,146 Clinical operations
Protocol enrollments 169,968 Clinical operations
Proﬁle OncoMap results 5148 Research
Proﬁle OncoPanel results 6378 Researchdata requests submitted by an investigator. A cross-disease committee
oversees requests that span multiple diseases. The user committees
also help in promoting collaborative research, by identifying similar re-
quests, and encouraging requesters to collaborate. The user committees
oversee data requests for de-identiﬁed, limited, and identiﬁed data. An
additional IRB human subject protection review is required for requests
for limited and identiﬁable data.
Designated disease user committee, and IRB, review signiﬁcantly re-
duces time required for data approval, therefore, accelerating opera-
tional efﬁciency.
2.1.4. Repeatability of results
In order to ensure repeatability of results, policies were enforced to
carry out systematic quality assurance (QA) and quality control (QC)
of data. The QA procedure scans data following any data movement
from the source systems to the data repository layer, and from data re-
pository layer into the access layer (Fig. 1). Any discrepancies found in
source data during the QA process is reported back to operational de-
partments whowill be responsible to ﬁx the problem in the source sys-
tems. Currently, clinical data in CORIS is refreshed every month while
genomic data in CRDR is refreshed twice a year. Rigorous data consis-
tency checks also help unearth any mismatches/issues in terms of pa-
tient information, sample identiﬁer, histology, tumor type, and genetic
abnormalities.
2.2. OncDRS components
OncDRS is composed of a suite of component tools: administrative
components, Aggregate Query Tool (AQT), which leverages the Infor-
matics for Integrative Biology and Bedside (i2b2) open source applica-
tion (Kohane et al., 2012), Data Request Engine (DRE), and Data
Extraction Engine (DEE). At a high level, these components enable an
authenticated and authorized faculty user to set up a project, manage
team members on their project, perform queries to deﬁne the cohorts,
Fig. 2. Real-time consent checking in OncDRS. CRDR, Consented Research Data Repository; CTMS, Clinical Trials Management System.
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using SAS and R. A screen shot of the SPARKS portal displaying OncDRS
capabilities is presented in Fig. 3. Faculty members who are also mem-
bers of the user committees can review data requests. User committee
chair and IRB members can review and approve requests — following
similar principles as a journal article review by an editorial board.
2.2.1. Administrative components
These tools are used to set up user accounts, project teams, and to
assign appropriate roles to each user. The authentication components
include LDAP authentication, to ensure that the user is an active institu-
tional member. Harvard Proﬁles authentication is done to ensure active
Harvard faculty status at the level of instructor or above. The project cell
of i2B2 is leveraged to ensure project-based access, and ability to share
query artifacts among collaborators.
2.2.2. Aggregate Query Tool (AQT)
The AQT includes hierarchy presentation and the query engine. The
i2b2 hierarchy presentation for clinical data was adapted and designed
hierarchy presentation for genomic data. AQT allows users to run
queries under three settings: 1) Same Patient level: meaning the patient
has the selected criteria at any point of time. For example, a patient was
dispensed carboplatin and had a thrombocytopenia at some point dur-
ing the care process. 2) Same date level: meaning that the patient has the
selected criteria on the same date. For example, a patientwas dispensed
carboplatin and had nausea and vomiting on the samedate. 3) Same pri-
mary cancer episode: meaning that the patient has the selected criteria
on the same episode of cancer. For example, a patient was given
carboplatin and had an adverse reactionwhen cancer site= breast, his-
tology = inﬂammatory carcinoma, clinical group stage = II. All project
team members can perform aggregate queries and can choose to share
queries with other team members or keep them private.Table 2
OncDRS user roles and privileges.
Permissions Faculty
member
Non-faculty member
To access the system data
dictionary
Yes Yes
To perform aggregate
queries
Yes Yes, if a faculty member grants access.
To request detailed patient
level data
Yes Yes, if a faculty member grants access. At
present submission of the request has to
be done by the faculty member.
To access detailed patient
data through system
Yes Not currently, but they will be able to if
listed in the protocol as collaborator
To create project teams
with multiple
collaborators
Yes No
To function as a disease user
committee chair or
member
Yes No2.2.3. Data Request Engine and Data Extraction Engine (DRE)
Thedata request and data extraction engine application components
collectively include the data request form, approval routing, Transient
Data Mart (TDM) generator, email sender, and data viewer. Users can
deﬁne cohorts using a previously run query or a Medical Record
Number (MRN) list, to specify the data categories of interest and specify
the disease program from which they are requesting data. All project
members can ﬁll in the request form, and the lead faculty member can
submit the request. An approval routing cycle is activated automatically
once a data request is submitted and the chair of the user committee of
the disease (or cross-disease) program from which the data is request-
ed, gets notiﬁed through email. The chair can then decide to route the
request to other members, request more information from the data re-
quester, or approve or deny requests. Once the disease committee chair
approves a request for limited or identiﬁable data, it gets routed to the
IRB. Once necessary approvals (Table 3) are in place, the TDMgenerator
extracts data on requested data categories on the speciﬁed cohort of pa-
tients identiﬁed through the AQT query, or theMRN list, attached to the
data request. A TDM database is created with user's identiﬁcation and
password is encapsulated. TDMs are locked from editing, are for view
only, and are connected to SAS and R to support easy analysis. TDMs
are available to the faculty requester only for the number of days spec-
iﬁed in the data request. In the meanwhile, the project identiﬁer, re-
leased patient sets, and user's credentials are collected in the database
for auditing purposes. A “Detailed Data Viewer” component provides
additional search and ﬁltering capabilities.
2.3. Technological architecture
OncDRS is an N-tier application. Fig. 4A displays architecture of the
system and Fig. 4B describes the deployment pattern of OncDRS. The
technological product stack used for OncDRS development is listed in
Table 4. The database tier contains a series of databases (AQT, IDM,
OncDRS, and Transient Data Mart (TDM) hosted mainly on Oracle data-
base servers. MySQL database will be used for retired TDMs for cost ef-
ﬁciency. Extract, Transform, Load (ETL) tools from Informatica (2100
Seaport Blvd, Redwood City, CA 94063) are used to make transmission
of data seamless, between the various OncDRS data storage layers. The
middle tier consists of core applications (Administrative components,
AQT DRE and DEE) on two different application servers (JBOSS 4.2.2
GA and Apache Tomcat 6.0.24). JBOSS is the default i2b2 server and is
required for AQT. Apache Tomcat server hosts all other application com-
ponents. The user interface (UI) tier spans across Client Browser and
Apache Webserver 2.2 (httpd). All database servers and application
servers are locatedwithin the institute's globalﬁrewall. Users can access
OncDRS either within the institute facilities or via VPN service to ensure
secure and private access of the system.
2.3.1. Data integration and honest broker
The OncDRS system transforms the “need to know” principle into an
honest broker system, which prevents unintentional disclosures. The
Table 3
OncDRS governing body approval requirements for different data types.
Data type Deﬁnition Review needed Module
Aggregate Patient count is returned for a given query. No review Aggregate Query Tool
De-identiﬁed All identiﬁable elementsa are set to null or modiﬁed to prevent patient identiﬁcation. Disease-based user committees Data request and data extraction
Limited Most identiﬁable elements are set to null or modiﬁed to prevent patient identiﬁcation. Disease-based user committees & IRB Data request and data extraction
Identiﬁed Identiﬁable elements are displayed, as they exist in the source system. Disease-based user committees & IRB Data request and data extraction
a Identiﬁable data elements include items such as medical record numbers, names, phone numbers, addresses, age, and encounter dates.
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ﬁers, and data is always identiﬁed in these two repositories (Fig. 1.).
Users do not have direct access to either of these repositories. The clin-
ical data is pushed into an Intermediate Data Mart (IDM) where each
patient is assigned an internal research master patient identiﬁer. OncDRS
only moves the research master patient identiﬁer into AQT, and leaves
the real patient identiﬁers in the IDM. Thus, unless a user speciﬁes a
need to review patient chart or to obtain “identiﬁers of patients who
may be appropriate for a study, and requests patient information with
identiﬁer or contact information in the data request form, the user can-
not identify the patient. Furthermore, patient counts returned by AQT
are always obfuscated by ±3, and no patient counts are provided if
the count is less than three. Obfuscation and blocking of low patient
counts were implemented as additional measures to prevent users
from determining patient identity using aggregate queries.
2.3.2. Real-time consent check
Even though a Proﬁle test will not be done until signed informed
consent is received from patients, a patient can change his/her mind
and withdraw the consent during or after the test is completed. One
of the critical features of the OncDRS application is a real-time con-
sent check mechanism to ensure that the answer is “yes” on the pri-
mary enrollment question before any data extraction and delivery
(Fig. 2.). If the consent status is “No” at the time of data release, the
patient's existing proﬁle test data will be excluded from the dataset
delivered to the TDM. These checks help ensure that a patient's con-
sent directives are followed even when a patient withdraws consent
after initial consent.Fig. 3. SPARKS portal displaying OncDRS capabilities. SPARKS, Synergistic Patien2.3.3. System security
OncDRS implements security in two stages: authentication and au-
thorization (Fig. 4A). Authentication is the ﬁrst stage of security check,
where OncDRS ensures that the user is indeed who he/she claims to
be. Authentication is implemented by using Partners Healthcare
System's (PHS) LDAP and Harvard University Proﬁles System. The sec-
ond stage is authorization that grants users permission to perform dif-
ferent functions in OncDRS based on the user's identity in accordance
with rules aforementioned, and outlined in Table 2. The project
management (PM) cell of i2B2 is used to enforce institutional policies
regarding privileges.
3. Discussion
Dana-Farber Cancer Institute has developed and implemented an
enterprise translational informatics system to integrate clinical and ge-
nomic data with HIPAA compliance. Since its launch in the summer of
2014, the system has successfully handled more than 1500 research
queries and has released data for more than 50 research studies. So far
the system has facilitated searches and data extractions of the following
broad categories:
• Feasibility assessment: are there enough number of patients that
match certain criteria for a potential clinical trial?
• Cohort identiﬁcation and recruitment for clinical trials: to identify the
potential list of participants for an open trial
• Correlative studies: extract all clinical andgenomic data on the follow-
ing for detailed analysis:t and Research Knowledge System; OncDRS, Oncology Data Retrial System.
Fig. 4.A. OncDRS Systemdetails. PHS, Partners Healthcare System; LDAP, Lightweight Directory Access Protocol; AQT, Aggregate Query Tool; TDM, Transient DataMart. B. OncDRS deploy-
ment diagram. PHS, Partners Healthcare System LDAP, Lightweight Directory Access Protocol; ONT, ontology; PM, project management; CRC, i2b2 Data Repository; IM, identity manage-
ment; CORIS, ClinicalOperational and Research Information System; CRDR, ConsentedResearchData Repository; AQT, Aggregate Query Tool; TDM, TransientDataMart; IDM, Intermediate
Data Mart.
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Table 4
Technological product stack used in OncDRS development.
Product OncDRS components Vendor
Java/JEE 1.6 Server side components Oracle Inc. — open source
Spring 3.0.4 Server side framework Spring.io — open source
Hibernate 3.4.0.GA ORM framework Hibernate.org — open source
Servlet 2.5 Server side components Oracle Inc. — open source
JSP 2.1 Web pages Oracle Inc. — open source
Mail 1.4.1 Email API Oracle Inc. — open source
displaytag 1.2 Web Presentation Library http://www.displaytag.org/1.2/
— open source
SiteMesh 2.4.2 Web Pages Theme
Library
http://wiki.sitemesh.org/ —
open source
Jaxb 2.1 Java XML Processing Library Oracle Inc. — open source
Log4j 1.2.26 Logger Library Apache Foundation — open
source
jQuery 1.4.2 Javascript UI Library https://jquery.com/ — open
source
Oracle database Oracle 11g Oracle Inc.
MySQL database MySQL 5.0.95 Oracle Inc. — open source
Data Integration &
ETL Tool
Power Center 9.1 Informatica
24 J. Orechia et al. / Applied & Translational Genomics 6 (2015) 18–25• Adult testicular cancer (ICD9: 186.9 and V10.52) patients diagnosed
(between 2008 and 2012) and received Cisplatin treatment in the
last 2 years.
• Prostate cancer patients (PSA levels 4–10) treated between 2005 and
2012.
• Primary ovarian cancer (with carcinoma and adenocarcinoma)
patients with selected variants.
The success of OncDRS in such a short period of time can be attribut-
ed to self-service capability and ease of use. One half hour training is
usually sufﬁcient for a new user to learn how to develop an aggregate
query, complete a data request form, and extract data for analysis.
Also, because AQT returns counts of patients in a matter of seconds,
users can easily get a good estimate of expected cohort size before
investing time in initiating research projects.
The modularity of OncDRS, by design, makes it easy to adapt to the
natural and anticipated evolution of software and scientiﬁc technology.
For example, test results from the Proﬁle OncoMap test, and the Proﬁle
OncoPanel test, which utilizes different technologies, have been suc-
cessfully integrated.
Although OncDRS is very efﬁcient in integrating and enabling access
to heterogeneous data, several opportunities to improve the system
have been identiﬁed. To ensure that the data requests are processed in
a timely and efﬁcient manner, user committee chairs and IRB directors
need to be provided with the ability to delegate administrative gover-
nance tasks to staff members.
Additionally, OncDRS does not efﬁciently support on-going clinical
trial recruitment, as the user currently needs to do a new data request
every time they need to get a list of potential candidate patients. Screen-
ing and selecting patients with particular genetic alterations for a clini-
cal trial are popular use-cases, and so, OncDRS needs to support
automated periodic generation of new recruiting lists based on a single
approved data request as long as the trial is open to accrual. Improve-
ments in the frequency of clinical and proﬁle data are also essential be-
cause current refresh cycles are not sufﬁcient to serve all the needs for
clinical trials recruiting.
AQT enables efﬁcient queries bymapping each concept into a row in
the observation_fact table and by encapsulating the concept and hierar-
chical structure in the metadata table. While this works perfectly with
clinical data, it may not lend well for future genomic queries. Currently
genetic alterations are mapped to a concept, and added into the
observation_fact table. With only 305 genes and limited genetic alter-
ations, the system works well. As we march into the era of the wholeexome and whole genome sequencing, the data will grow exponential-
ly. Modeling a vast number of genetic variations in a hierarchy may be-
come unrealistic. A hybrid approach with hierarchy presentation on
clinical data side and an integrated new module for genomic data
could be a potential solution and needs to be explored.
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